BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 10-Q — Nov 16, 2026
BrainStorm Cell Therapeutics filed its Q3 2026 10-Q with substantial doubt about its ability to continue as a going concern, reporting just $348,000 in cash, cash equivalents and restricted cash against a $12.7 million working capital deficit. The company's net loss for the nine months ended September 30, 2026 was $7.7 million, and it has never generated revenue. It was delisted from Nasdaq in 2025 and now trades on OTCQB, and management disclosed a material weakness in internal controls over short-term loan transactions that has not yet been remediated.
Key figures
- Total Assets
- 840000
- Cash Position
- 163000
- Shares Outstanding
- 14259377
- Restricted cash
- 185000
- Rnd nine months
- 2248000
- Accounts payable
- 7473000
- Short term loans
- 1875000
- Ichilov claim nis
- 2117950
- Net cash financing
- 2991000
- Accumulated deficit
- 245000000
- Cash restricted total
- 348000
- Working capital deficit
- 12719000
- Total current liabilities
- 13172000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.